Compared to Oral Sumatriptan, AVP-825 Reduces Disability by Relieving Migraine Severity: An Analysis from the COMPASS Study

James S. McGinley, PhD; RJ Wirth, PhD; Dawn C. Buse, PhD; Ken Shulman, DO; Richard B. Lipton, MD (2017). Compared to Oral Sumatriptan, AVP-825 Reduces Disability by Relieving Migraine Severity: An Analysis from the COMPASS Study. Poster (PO-01-045) to be presented at the 18th Congress of the International Headache Society in Vancouver, Canada.